The biopharma company, formerly US Genomics, has closed an $11.5m series B round with investment from Ascension Health and Cain Brothers among others.
US-based biopharmaceutical company PathoGenetix closed its series B funding round yesterday at $11.5m, having raised a second tranche of $7.5m to add to the $4m it raised in July.
Ascension Health Ventures, a division of non-profit healthcare management company Ascension Health, venture capital firms HealthCare Ventures and Excel Venture Management, and CB Ventures, the venture capital division of investment bank Cain Brothers, all participated in the round.
PathoGenetix raised $1.5m in December last year at around the same time as…
